{"url_path":"/sec/cik-0001119643/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 Executive Compensation**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1119643/0001493152-26-024641-index.html","accession_number":"0001493152-26-024641","cik":"0001119643","ticker":null,"issuer_name":"NUTRA PHARMA CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1119643/0001493152-26-024641-index.html","primary_entity_key":"0001119643","primary_entity_name":"NUTRA PHARMA CORP"},"word_count":354,"has_tables":true,"body_markdown":"**Item\n11. Executive Compensation**\n\n \n\nThe\nfollowing table summarizes compensation information for the last two fiscal years for (i) our Chief Executive Officer and (ii) the most\nhighly compensated executive officer other than the Chief Executive Officer who was serving as our executive officer at the end of the\nfiscal year (collectively, the “Named Executive Officers”).\n\n \n\nThe\nfollowing executive compensation disclosure reflects all compensation awarded to, earned by or paid to the executive officers below,\nfor the fiscal years ended December 31, 2025 and 2024.\n\n \n\n**SUMMARY\nCOMPENSATION TABLE**\n\n \n\nName and principal\nPosition \nYear  \n\n**Salary**\n\n**($)(2)**\n  \n\n**Bonus**\n\n**($)**\n  \n\n**Stock Awards**\n\n**($)**\n  \n\n**Option Awards**\n\n**($)**\n  \n\n**Non- Equity Incentive Plan Compensation**\n\n**($)**\n  \n\n**Nonqualified Deferred Compensation Earnings**\n\n**($)**\n  \nAll Other\nCompensation\n($)  \nTotal\n($) \n\nMichael Flax \n2025  \n 144,000  \n —  \n —  \n —  \n —  \n —  \n —  \n 144,000 \n\nChief Executive Officer,\nChief Financial Officer,\nPresident and\nChairman of the Board (1) \n2024  \n 111,097  \n —  \n —  \n —  \n —  \n —  \n —  \n 111,097 \n\n  \n   \n    \n    \n    \n    \n    \n    \n    \n   \n\nDale Vanderputten \n2025  \n 144,000  \n —  \n —  \n —  \n —  \n —  \n —  \n 144,000 \n\nChief Scientific Officer \n2024  \n 144,000  \n —  \n —  \n —  \n —  \n —  \n —  \n 144,000 \n\n \n\n \n(1)\nSubsequent\nto the settlement with the SEC in March of 2024, Michael Flax, DDS. was appointed as our Chairman, CEO and CFO\n\n \n \n \n\n \n(2)\nRepresents\nsalary accrued or paid during 2025 and 2024, respectively\n\n \n\nThe\nfollowing director compensation disclosure reflects all compensation awarded to, earned by or paid to the directors below for the fiscal\nyears ended December 31, 2025 and 2024.\n\n \n\n**DIRECTOR\nCOMPENSATION**\n\n \n\nName \n\n**Fees Earned**\n\n**or Paid in Cash**\n\n**($)**\n  \n\n**Stock**\n\n**Awards**\n\n**($)**\n  \n\n**Option**\n\n**Awards**\n\n**($)**\n  \n\n**Non-Equity**\n\n**Incentive Plan**\n\n**Compensation**\n\n**($)**\n  \n\n**Nonqualified**\n\n**Deferred Compensation**\n\n**Earnings**\n\n**($)**\n  \n\n**All Other**\n\n**Compensation**\n\n**($)**\n  \n\n**Total**\n\n**($)**\n \n\nStewart Lonky \n 0  \n 0  \n 0  \n 0  \n 0  \n 0  \n 0 \n\nGarry Pottruck \n 0  \n 0  \n 0  \n 0  \n 0  \n 0  \n 0 \n\n \n\n**Director\nCompensation**\n\n \n\nThere\nare no standard arrangements to which directors are compensated for services provided to us. Should we obtain adequate funding or sufficient\nrevenues to justify standard arrangements for director compensation, we will consider whether to adopt such a compensation plan.\n\n \n\n**Stock\nOption Grants in Last Fiscal Year**\n\n \n\nWe\ndid not grant incentive and non-qualified stock options in 2025 to any executive officer or director.\n\n \n\n41"}